Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
29/09/2026 12:09
BRIEF-Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock Sept 29 (Reuters) - Immix Biopharma, Inc. IMMX.O:
IMMIX BIOPHARMA ANNOUNCES PRICING OF $125 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK
IMMIX BIOPHARMA, - PRICES 11,363,637 SHARES AT $11 PER SHARE
IMMIX BIOPHARMA, - NET PROCEEDS TO FUND NXC-201 DEVELOPMENT, WORKING CAPITAL, CORPORATE PURPOSES
Source text: ID:nGNXbTmdgC
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary